Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy

Status: No longer recruiting

Protocol number: ML16633

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, double-blind study of 2 dose levels of Kytril on the prevention of post-operative nausea and vomiting in pediatric patients undergoing surgery with general anesthesia

Brief summary: This 2 arm study will evaluate the efficacy and safety of a single intravenous injection of Kytril in preventing PONV in children. Patients will be randomized to receive a single dose of either 20 micrograms or 40 micrograms Kytril iv 15 minutes prior to the end of surgery with general anesthesia for tonsillectomy or adenotonsillectomy. The anticipated time on study treatment is <3 months, and the target sample size is 100-500 individuals. Target sample size is 171.

Study phase: IV

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Parallel; Safety/Efficacy study

Condition: Post-Operative Nausea and Vomiting

Intervention type: Drug

Intervention name: granisetron [Kytril]

Primary outcome: 1. Percentage of patients with no vomiting Time frame: 0-2h after end of surgery (time of extubation)

Key secondary outcomes: 1. Percentage of patients with no vomiting Time frame: 0-24h after time of extubation 2. Time to first vomiting episode Time frame: Event driven 3. Adverse experiences Time frame: Throughout study

Inclusion criteria:

  • males and females 2-16 years of age
  • scheduled to undergo elective surgery for tonsillectomy or adenotonsillectomy requiring general anesthesia and endotracheal intubation
  • scheduled for hospital admission for no longer than 24 hours

Exclusion criteria:

  • known allergy or other contraindication to the use of Kytril or any of its components
  • known allergy to any other 5HT3 antagonist
  • history of motion sickness or post-operative nausea or vomiting
  • nausea or vomiting in the 24 hours prior to anesthesia

Gender: Males or Females

Age limits: Min: 2 Years Max: 16 Years

Accepts healthy volunteers: No

Anticipated start date: April, 2007

Trial registration date: 08/31/2005

Date last updated: 8/29/2008


Link to trial result

This trial was conducted at the following locations:

United States

  • Fresno, CA
  • Stanford, CA
  • Hartford, CT
  • Miami, FL
  • Boston, MA
  • Pittsburgh, PA
  • Nashville, TN
  • Dallas, TX

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply